Comparative Pharmacology
Head-to-head clinical analysis: DELATESTRYL versus TESTRED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DELATESTRYL versus TESTRED.
DELATESTRYL vs TESTRED
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Testosterone ester; binds to androgen receptors, activating gene transcription and promoting protein synthesis, muscle growth, and secondary sexual characteristics.
Testosterone is an androgen receptor agonist, promoting development of male secondary sexual characteristics and anabolic effects.
50 to 200 mg intramuscularly every 2 to 4 weeks.
Testosterone enanthate 200 mg intramuscularly every 2 weeks.
None Documented
None Documented
8 days (terminal); requires 5-6 weeks to reach steady state with weekly dosing
Terminal elimination half-life for testosterone is 2-4 hours; testosterone enanthate has a half-life of 4-5 days due to slow release from the oily depot. Clinical context: shorter half-life requires more frequent dosing for stable serum levels.
Urinary (90% as glucuronide and sulfate conjugates, 5% as unchanged drug); fecal (5%)
Approximately 90% of administered testosterone is excreted in urine as glucuronide and sulfate conjugates of testosterone and its metabolites (androsterone, etiocholanolone). About 6% is excreted in feces via bile. Unchanged testosterone excretion is negligible (<1%).
Category C
Category C
Androgen
Androgen